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Abstract
Background: Airway inflammation and airway hyperresponsiveness (AHR) are two characteristic
features of asthma. Fractional exhaled nitric oxide (FENO) has shown good correlation with AHR
in asthmatics. Less information is available about FENO as a marker of inflammation from work
exposures. We thus examined the relation between FENO and AHR in lifeguards undergoing
exposure to chloramines in indoor pools.
Methods: 39 lifeguards at six indoor pools were given a respiratory health questionnaire, FENO
measurements, spirometry, and a methacholine bronchial challenge (MBC) test. Subjects were
labeled MBC+ if the forced expiratory volume (FEV1) fell by 20% or more. The normalized linear
dose-response slope (NDRS) was calculated as the percentage fall in FEV1 at the last dose divided
by the total dose given. The relation between MBC and FENO was assessed using logistic
regression adjusting on confounding factors. The association between NDRS and log-transformed
values of FENO was tested in a multiple linear regression model.
Results: The prevalence of lifeguards MBC+ was 37.5%. In reactors, the median FENO was 18.9
ppb (90% of the predicted value) vs. 12.5 ppb (73% predicted) in non-reactors. FENO values ≥ 60%
of predicted values were 80% sensitive and 42% specific to identify subjects MBC+. In the logistic
regression model no other factor had an effect on MBC after adjusting for FENO. In the linear
regression model, NDRS was significantly predicted by log FENO.
Conclusions:  In lifeguards working in indoor swimming pools, elevated FENO levels are
associated with increased airway responsiveness.
Background
Airway inflammation is the hallmark of asthma[1]. Expo-
sure to a variety of agents in the workplace can cause air-
way inflammation and occupational asthma. Thus,
investigating airway inflammation from work exposure is
important to elaborate preventive strategies.
Airway hyperresponsiveness (AHR) can be considered as a
surrogate marker of airway inflammation and is recog-
nized as another characteristic finding of asthma[1]. In
the general population, AHR is a risk factor for an acceler-
ated decline in forced expiratory volume in one second
(FEV1) and for the development of asthma and chronic
Published: 31 December 2009
BMC Pulmonary Medicine 2009, 9:53 doi:10.1186/1471-2466-9-53
Received: 30 April 2009
Accepted: 31 December 2009
This article is available from: http://www.biomedcentral.com/1471-2466/9/53
© 2009 Demange et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Pulmonary Medicine 2009, 9:53 http://www.biomedcentral.com/1471-2466/9/53
Page 2 of 9
(page number not for citation purposes)
obstructive pulmonary disease[2]. In working popula-
tions, AHR is an important determinant for the develop-
ment of symptoms[3].
Fractional concentration of exhaled nitric oxide (FENO) is
another indirect marker of airway inflammation. FENO is
increased in subjects with established asthma[4], is a
more accurate detector of asthma than conventional
tests[5], and has proved useful to monitor asthma treat-
ment[6]. Moreover, the test is simple, quick to perform
and has good reproducibility[7]. In working populations,
elevated FENO levels have been found in non-smoking
aluminium potroom workers[8], in underground con-
struction workers[9], in shoe and leather workers[10], and
in bleachery workers[11].
AHR correlates with FENO in steroid naïve asthmat-
ics[12], adolescents in clinical remission of asthma[13],
and atopic adults, asthmatics or not[14]. However, less is
known about the relationship between AHR and FENO in
workers undergoing exposure to pollutants in the work-
place. Knowledge on this topic would help to better
define the use of FENO as a tool in respiratory epidemiol-
ogy.
The present study was carried out as a preliminary study
to assess whether, in the context of occupation respiratory
studies carried out in populations at work, the FENO
could usefully complement the more traditional, but
more difficult to use, methacholine bronchial challenge
(MBC) test. This preliminary study was performed in a
population of lifeguards working in indoor swimming
pools, an occupation in which we had demonstrated a
high prevalence of AHR in a previous study[15]. The pur-
pose of the present paper is to show the feasibility of this
approach and to examine the cross-sectional relationship
between FENO and AHR as measured by the MBC test.
Methods
The study was a cross-sectional survey of lifeguards from
all six indoor swimming pools in an urban area of Eastern
France. The examinations took place between April and
June 2006 between 9:00 and 12:00 AM, or between 14:00
and 17:00 PM if morning examinations were not possible.
The whole workforce was invited. Lifeguards with current
asthma, not needing a corticosteroid treatment, and not
in crisis, were included. All subjects gave written informed
consent. The study was approved by the local medical eth-
ics committee, Comité Consultatif de Protection des Per-
sonnes se prêtant à la Recherche Biomédicale de Lorraine,
located in Nancy, France.
Symptoms and smoking habits
A standard questionnaire indicated the past and present
personal histories of cough, phlegm, physician-diagnosed
asthma, wheezing, and dyspnea[15]. It included ques-
tions about work-related, irritant symptoms (ocular,
nasal, respiratory) and a personal history of physician-
diagnosed allergies (hay fever or eczema or urticaria).
Non-smokers were defined as subjects who had never regu-
larly smoked one or more cigarettes a day, or had smoked
one or more cigarettes a day for less than one year. Smokers
were defined as subjects who reported regular smoking of
one or more cigarettes a day for at least one year. Ex-smok-
ers were subjects who reported smoking one or more cig-
arettes a day regularly in the past but who had quit
smoking at least one year prior to the study.
FENO
FENO was measured using a chemiluminescence analyzer
(Endono 8000, Seres, Aix en Provence, France) according
to ATS/ERS recommendations[16]. The subject was in a
sitting position and exhaled against an oral pressure of 5
cmH20 -- sufficient to close the velum - at a constant flow
of 50 mL.s-1; measurements were expressed in parts per
billion (ppb). Calibrations were performed at the begin-
ning of the study and then checked daily. Exhalations
were repeated until the performance of three values that
varied < 10%[16]. Subjects avoided eating, drinking,
smoking, and/or exercising for at least 1 hour before test-
ing. FENO measurements were expressed in ppb and as a
percentage of the predicted value according to Olin and
colleagues[17]. They used height, weight, age, gender,
tobacco status, atopy based on total amount of IgE, physi-
cian-diagnosed asthma, asthma symptoms during the pre-
vious month and reported use of inhaled steroids. We
used the same factors excepted for atopy, replaced by self-
reported history of physician-diagnosed allergies. No sub-
ject needed corticosteroid treatment or had had a crisis in
the previous month. Measurements were taken before
spirometry and methacholine bronchial challenge (MBC)
test.
Pulmonary function and airway responsiveness
Spirometry was carried out using an electronic spirometer
(SpiroStar DXMedikro, L21, St-Germain-en-Laye, France).
Forced Vital Capacity (FVC), forced expiratory volume in
one second (FEV1), and maximal expiratory flows at vari-
ous lung volumes were obtained according to ATS recom-
mendations[18]. Results are presented as the ratio or the
difference between the observed and predicted values. Air-
way responsiveness to methacholine was determined
using a technique in accordance with published guide-
lines[19] in an abbreviated version[20]. Only three cumu-
lative doses of methacholine (0.5, 2.5, 7.5 μmol) were
administered in sequence using a nebulizer (Mediprom
FDC88, Paris, France) delivering doses of 0.5 μmol of
methacholine per breath. The system is equipped with a
nebulizer De Vilbiss delivering particles 3 μm in diameter.
Spirometry was performed just before and three minutesBMC Pulmonary Medicine 2009, 9:53 http://www.biomedcentral.com/1471-2466/9/53
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after the inhalations. The test was discontinued either
after the inhalation of the last dose or if the FEV1 fell by ≥
20% below the baseline value, defining a positive MBC
test (MBC+). A linear dose-response slope (DRS) was cal-
culated as the percentage decrease in FEV1 at last dose
divided by the total administered dose [21]. In order to
apply the multiple regression analysis to the DRS, the data
was normalized. This normalized dose-response slope
(NDRS) transformation (1/(%decrease in FEV1/metha-
choline μmol +2.5)) had been found to be optimal in a
large unexposed population [22]; greater values of NDRS
indicating lower AHR.
Statistical analysis
Statistical analysis was carried out using the Stata package
(Stata, College Station, TX, USA). FENO (in ppb and in
percentage of the predicted value) was expressed as
median and quartiles. Logistic regression analysis was
used to assess the relation between MBC+ and FENO
adjusting on age, gender, atopy, and FEV1. A value of p <
0.05 was considered significant. Furthermore, the associa-
tion between NDRS and log-transformed values of FENO
was tested in a multiple linear regression model adjusting
on the same variables as in the logistic regression analysis.
Results
Forty-eight lifeguards were invited; 44 subjects (32 men,
12 women) agreed to participate (rate of participation:
92%). One subject refused to perform the MBC test while
the curves produced by three subjects were unacceptable.
One subject had infectious rhinitis. Therefore, 39 partici-
pants (29 men; 10 women) were included in the analyses.
The general baseline characteristics and features of respi-
ratory function, airway responsiveness, and symptoms are
shown in Table 1. There were two childhood asthmatics
who had not suffered a crisis since adolescence and two
adult-onset asthmatics, not having a crisis at the time of
Table 1: Characteristics of lifeguards
Males (n = 29) Females (n = 10)
Age (yr, mean (sd)) 35.9 (8.8) 33.3 (10.0)
Height (cm, mean (sd)) 180.4 (7.6) 168.3 (7.7)
Smokers (n, (%)) 9 (31) 4 (40)
Former smokers (n, (%)) 5 (17) 1 (10)
Non-smokers (n, (%) 15 (52) 5 (50)
FEV1
(L, mean (sd)) 5.09 (0.69) 3.83 (0.47)
(% predicted, mean (sd)) 121.0 (15.7) 119.7 (11.3)
FVC
(L, mean (sd)) 6.34 (0.69) 4.53 (0.48)
(% predicted, mean (sd)) 124.4 (11.5) 123.2 (10.9)
FEV1/FVC
(% observed, mean (sd)) 80.3 (6.1) 84.4 (4.7)
(% predicted, mean (sd)) 99.5 (8.0) 102.0 (4.9)
Airway responsiveness
MBC+ (n, (%)) 11 (37.9) 4 (40.0)
NDRS (mean (sd)) 0.22 (0.09) 0.19 (0.09)
Personal history of allergy ((n, (%)) 2 (6.9) 3 (30.0)
Acute work-related symptoms (n, (%))
Ocular 21 (72.4) 7 (70.0)
Nasal 15 (51.7) 5 (50.0)
Laryngeal 14 (48.3) 3 (30.0)
FEV1: Forced Expiratory Volume in one Second; FVC: Forced Vital Capacity
MBC: Methacholine Bronchial Challenge test
MBC+: decrease of 20% or more below the baseline value of FEV1 in a methacholine bronchial challenge test.
NDRS: Normalized Dose Response SlopeBMC Pulmonary Medicine 2009, 9:53 http://www.biomedcentral.com/1471-2466/9/53
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testing and not receiving corticosteroid treatment. One of
the former and the two latter were classified as having a
positive MBC test (MBC+).
The proportion of current smokers was greater among
females (40%) than among males (31%); since the
number of ex-smokers was so small, we chose to classify
them as non-smokers. Overall, pulmonary function val-
ues exceeded the predicted ones both among males
(121%) and females (119%) for the FEV1. Two men (2/
29 = 6.9%) and three women (3/10 = 30.0%) reported a
personal history of allergy. No cases of chronic bronchitis
or dyspnea were recorded. However, there was a high
prevalence of acute, irritant symptoms both among males
and females, with prevalence rates ranging from 30.0%
for laryngeal irritation among females to 72.4% for ocular
symptoms among males.
Of the 39 lifeguards, 15 (38.5%) were classified as having
MBC+. From these, 11 were males and four were females,
thus giving prevalence rates of 37.9% and 40.0% respec-
tively.
FENO for the whole group was not normally distributed.
The median FENO values for reactors and non-reactors
stratified by sex and smoking status are shown in Table 2.
The median FENO in reactors was 18.9 ppb (11.9 to 36.3
ppb; 59.6 to 219.9% predicted), whereas in non-reactors
it was 12.5 ppb (8.2 to 17.3 ppb; 44.2 to 96.5% pre-
dicted). A similar trend toward greater FENO values
among reactors was noticed across all male subgroups but
less so among females; however, the latter subgroups were
too small for comparison.
The distribution of FENO in reactors and non-reactors is
shown in Figure 1 (FENO in percent predicted and FENO
in ppb). The distribution of lifeguards according to the
arbitrary FENO cutoff point of 60% of the predicted value,
and according to MBC+ or MBC- groups was as follows:
FENO ≥ 60% (11 MBC+/14 MBC-); FENO < 60% pred.: (4
MBC+/10 MBC-). The sensitivity was 80%, the specificity
42%, the positive predictive value 44% and the negative
predictive value 71%. FENO had an effect on AHR adjust-
ing or not on atopy, smoking, and FEV1 in the logistic
regression model. Similarly, none of these factors had a
significant effect on AHR when adjusting on FENO.
Reactors tended to have greater FENO values and smaller
NDRS values than non-reactors (Figure 2). In a multiple
linear regression model predicting NDRS adjusted on sex,
smoking, FEV1 (difference between observed and pre-
dicted values) and atopy (Table 3), log FENO was a signif-
icant predictor (p = 0.01) as was atopy (p = 0.02).
Discussion
This study showed that the concentration of FENO in life-
guards working in indoor swimming pools correlates sig-
nificantly with the degree of airway responsiveness
measured with methacholine; this relationship was not
affected by smoking status, gender, or self-reported his-
tory of allergies. Furthermore, the 60% of predicted value
cutoff-point for "abnormal" FENO was sensitive in dis-
criminating reactors from non-reactors. To our knowl-
edge, no similar data have been collected previously in
working populations.
There was a high prevalence of AHR among male (37.9%)
and female (40.0%) lifeguards. These prevalence rates are
higher than but comparable with the corresponding rates
(13.7% males; 28.2% females) reported previously in
another population of indoor lifeguards[15]. The clinical
significance of AHR in our subjects is not straightforward
as the population contains only two prevalent asthmatics.
Indeed, although AHR is a common feature of asthma,
dissociation between AHR and inflammation has been
documented[23] so the exact mechanism by which
inflammation causes AHR is unknown.
FENO levels are correlated with eosinophilic airway
inflammation in asthmatics and the test has been pro-
posed for asthma-screening in young adults[24]. How-
Table 2: FENO (median [percentile 25, percentile 75] in ppb and 
as % predicted) in reactors and non-reactors stratified by sex and 
smoking status
MBC - MBC+
FENO FENO
n ppb n ppb
(%pred) (%pred)
All 24 12.5 [8.2, 17.3] 15 18.9 [11.9, 36.3]
(73.5 [44.2, 96.5]) (90.1 [59.6, 219.9])
Males 18 13.7 [8.7, 19.2] 11 22.4 [15.4, 36.3]
(73.5 [44.3, 99.0]) (118.2 [77.7, 219.9])
Smokers 6 9.8 [7.3, 14.8] 3 17.1 [7.6, 30.1]
(64.5 (44.0,103.7]) (131.8 [55.5, 219.9])
Non-smokers 12* 14.8 [9.9, 19.8] 8** 26.1 [17.1, 45.9]
(78.0 [48.6, 96.5)) (104.2 [78.4, 199.7])
Females 6 9.6 [7.1, 13.8] 4 11.5 [10.8, 37.2]
(71.3 [39.9, 93.6]) (65.6 [54.8, 177.5])
Smokers 3 13.8 [10.1, 24.5] 1° 11.1
(93.6 [88.8,196.8]) (71.5)
Non-smokers 3 7.1 [4.8, 9.1] 3°° 11.9 [10.5, 62.5]
(39.9 [25.1, 53.7]) (59.6 [49.9, 283.6])
* one with a history of allergies FENO = 7.6 ppb (24.9% pred)
** one with a history of allergies FENO = 36.3 ppb (118.2% pred)
° one with a history of allergies
°° two with a history of allergies FENO = 10.5 ppb (49.9% pred) and 
62.5 (283.6% pred)BMC Pulmonary Medicine 2009, 9:53 http://www.biomedcentral.com/1471-2466/9/53
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Distribution of measured FENO in reactors (MBC+) and non-reactors (MBC-) Figure 1
Distribution of measured FENO in reactors (MBC+) and non-reactors (MBC-).
4
7
10
3
44
3
4
0
2
4
6
8
1
0
1
2
 30%
50%
80%
100%
150%
200%
300%
 30%
50%
80%
100%
150%
200%
300%
MBC- MBC+
 
FENO expressed in percent of predicted (Olin 2006)
18
5
1
7
4
11
2
0
2
4
6
8
1
0
1
2
1
4
1
6
1
8
2
0
0 20 40 60 80 0 20 40 60 80
MBC- MBC+
 
FENO expressed in ppbBMC Pulmonary Medicine 2009, 9:53 http://www.biomedcentral.com/1471-2466/9/53
Page 6 of 9
(page number not for citation purposes)
ever, the significance of elevated FENO in workers
without overt asthma remains unclear. The few published
studies on this topic found high FENO levels in workers
exposed both to sensitizers and irritants[8-10], a finding
suggesting that eosinophilic inflammation might not be
the only mechanism to explain the increased NO produc-
tion in workers. Incidentally, studies of endurance ath-
letes, - a population closer to our lifeguards than
asthmatics -, did not find a correlation between increased
FENO and eosinophil counts in induced sputum[25].
Bearing in mind the above considerations and the known
mechanisms of NO production[26], we are tempted to
speculate that the raised FENO levels in reactors could be
due to sub-clinical airway inflammation caused by expo-
sure to the highly irritant chloramine NCl3. The extent to
which such inflammation is eosinophilic in nature or not
is irrelevant since exposure to pollutants can raise NO pro-
duction by eliciting changes in oxide synthase but also
though oxidative stress[10,27]. In addition, an increase in
the permeability of airway epithelium to allergens due to
chloramines has been described in lifeguards[27] and
could have played a role in our subjects, although, in this
case, we would have expected a better correlation with
atopy. Whether this high prevalence of AHR and concom-
itant high levels of FENO is however due to any specific
exposure is beyond the scope of this paper.
Atopy is important in the relationship between FENO and
AHR. Verges and colleagues[25] showed that endurance
athletes with AHR had significantly higher FENO levels
and were more frequently atopic than subjects without
AHR. Franklin and colleagues[28] showed elevated FENO
in atopic children AHR+ but not in atopic children AHR-.
Subsequently, the same team showed similar findings in
the parents of these children, with an intriguing negative
association between FENO and DRS in non-atopic sub-
jects and a positive association in the atopic ones, asthma
being not directly related to levels of FENO once the inter-
action FENO atopy was accounted for[14]. To the extent
that a personal history of allergies can be equated with
atopy, our results are at variance with these data. While we
acknowledge that the number of our workers reporting
allergies was small, we must stress that this parameter is
more closely related to the risk of work related symptoms
over time than to atopy based on a skin prick test[29]. Fur-
thermore, personal history of allergy has been reported to
be as efficient as positive skin prick tests to common aller-
gens in detecting associations between atopic diathesis
and allergic respiratory diseases in working populations,
including animal handlers, bakers, and workers exposed
to latex[29]. However, it is possible that undetected atopy
could explain part of the association between FENO and
AHR. However, given that this is the second population of
lifeguards in which we observed a high prevalence of
AHR, it is highly unlikely that this finding is due to atopy
alone.
We used 60% of the predicted values of Olin and col-
leagues[17] as a cutoff-point for "abnormal" FENO for
three reasons. First, current guidelines do not yet specify
"normal" values and evidence is accumulating that the
"optimal" cutoff point for screening for asthma will not
necessarily be suitable for other populations. Second,
unlike others, the equations proposed by Olin and col-
leagues[17] take into account some of the most known
confounding factors namely atopy, gender, and smoking
status. Finally, given the preliminary character of this
study, a rough threshold -- chosen by visual inspection of
the distribution of FENO (Figure 1) -- was enough for us
to test our strategy.
One strength of this study was the quality of data collec-
tion. Our team has been measuring airway responsiveness
for almost two decades and our technique is well stand-
ardized. In addition, FENO measurements are simple to
perform and were carried out according to current guide-
lines at constant expiratory flows of 50 mL.s-1 and system-
atically before spirometry and methacholine challenge. In
this respect, the differences we observed between smokers
versus non-smokers (Table 2) is in agreement with recent
studies[17] including our own[7]. Concerning limita-
Table 3: Multiple linear regression models of normalized dose response slope according to log FENO in percent predicted, difference 
between observed and predicted FEV1, sex, smoking status, and personal history of allergies.
Normalized dose response slope
coefficient 95% CI p
Log FENO (% predicted) -0.119 [-0.210;-0.029] 0.011
Difference between observed and predicted FEV1 0.009 [-0.012;0.030] 0.373
Sex
Male versus female 0.025 [-0.035;0.085] 0.399
Smoking status
Smokers versus non smokers 0.052 [-0.001;0.105] 0.056
Personal history of allergies versus no personal history -0.090 [-0.168;-0.013] 0.024
95% CI: 95% confidence intervalBMC Pulmonary Medicine 2009, 9:53 http://www.biomedcentral.com/1471-2466/9/53
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Association between Normalized Dose Response Slope and measured FENO in reactors (MBC+) and non-reactors (MBC-) Figure 2
Association between Normalized Dose Response Slope and measured FENO in reactors (MBC+) and non-
reactors (MBC-).
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tions, our sample size was indeed small but represented
recruitment from all indoor pools in our region. Notwith-
standing, we were able to document a significant relation-
ship between FENO levels and two indices of AHR in
apparently healthy lifeguards, which was the main reason
for this preliminary study. In this context, a non-exposed,
control group would have added little to this evidence.
Conclusions
In conclusion, our results suggest that FENO measure-
ments are potentially useful in detecting workers with
AHR considered as a risk factor for the development of
symptoms. Using a less than optimal cutoff-point for
"abnormal" FENO, we showed that high FENO values are
associated with AHR while low FENO values tended to be
associated with normal airway responsiveness. Further
prospective longitudinal studies exploring the relation-
ship between FENO and AHR are necessary to improve
our knowledge of the significance of FENO in working
populations.
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